Question · Q4 2025
Dan Rizzo asked about the long-term growth outlook for emergency medicine (Narcan) after the current headwinds stabilize, and how the company assesses the strength of the winter cough and cold season and its impact on the consumer healthcare outlook.
Answer
CEO Stephan Tanda indicated expectations for low to mid-single-digit growth for emergency medicine from a new baseline, driven by continued use by first responders and harm reduction efforts. He noted that consumer healthcare destocking is behind them and back to growth, with updates on the flu season's impact expected by the Q1 or Q2 call.
Ask follow-up questions
Fintool can predict
ATR's earnings beat/miss a week before the call
